Physiologically Based Biopharmaceutics Model of Apixaban for Biopharmaceutics Risk Assessment

<b>Background/Objectives:</b> This study applies a Physiologically Based Biopharmaceutics Modeling (PBBM) framework to predict the bioavailability (BA) and bioequivalence (BE) of apixaban, a borderline BCS Class III/IV drug. It investigates how formulation factors, such as particle size,...

Full description

Bibliographic Details
Published in:	Pharmaceutics
Main Authors:	Paulo Paixão, Zvonimir Petric, José A. G. Morais
Format:	Article
Language:	English
Published:	MDPI AG 2025-03-01
Subjects:	Physiologically Based Biopharmaceutics Modeling apixaban model-informed drug development Critical Biopharmaceutics Attributes
Online Access:	https://www.mdpi.com/1999-4923/17/3/382

Similar Items

The emerging role of physiologically-based pharmacokinetic/biopharmaceutics modeling in formulation development
by: Cvijić Sandra, et al.
Published: (2021-01-01)

The production of biopharmaceuticals in Brazil: current issues
by: Marcela Valente Pimenta, et al.
Published: (2019-12-01)

Strategic aspects of staffing industrial biopharmaceutical companies
by: A. S. Glazkova, et al.
Published: (2020-01-01)

In Silico Evaluation of the Biopharmaceutical and Pharmacokinetic Behavior of Metronidazole from Coated Colonic Release Matrix Tablets
by: Roberto Arévalo-Pérez, et al.
Published: (2025-05-01)

Status of the Indian biopharmaceutical industry and way forward to be a dominant global player
by: Prasanta Kumar Ghosh
Published: (2023-01-01)

Integrating In Vitro BE Checker with In Silico Physiologically Based Biopharmaceutics Modeling to Predict the Pharmacokinetic Profiles of Oral Drug Products
by: Takuto Niino, et al.
Published: (2025-09-01)

What are biopharmaceuticals?
by: Abhay H. Pande, et al.
Published: (2025-01-01)

Advances in biopharmaceutical products for hemophilia
by: Junzheng Wu, et al.
Published: (2024-12-01)

Microneedle-Mediated Transdermal Delivery of Biopharmaceuticals
by: Hiep X. Nguyen, et al.
Published: (2023-01-01)

Subcutaneous Biopharmaceutics: Building tools for a flexible future
by: Kate Louise Harris, et al.
Published: (2023-12-01)

DEVELOPMENT PROSPECTS OF BIOPHARMACEUTICAL PLANTS IN PALEMBANG CITY
by: Meri Ariyantini, et al.
Published: (2021-12-01)

Hybrid modeling for biopharmaceutical processes: advantages, opportunities, and implementation
by: Harini Narayanan, et al.
Published: (2023-05-01)

BIOPHARMACEUTICAL PROPERTIES OF THE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
by: Y. I. Kulinich
Published: (2012-03-01)

Integrating In Vitro Biopharmaceutics into Physiologically Based Biopharmaceutic Model (PBBM) to Predict Food Effect of BCS IV Zwitterionic Drug (GSK3640254)
by: Konstantinos Stamatopoulos, et al.
Published: (2023-02-01)

Introducing the open innovation model in Polish biopharmaceutical companies: major drivers and barriers
by: Małgorzata Runiewicz-Wardyn, et al.
Published: (2023-03-01)

Surge Dose<sup>®</sup> Formulations of NSAIDs Provide for Ultra-Rapid and Consistent Drug Absorption in Both the Fasted and Fed State as Predicted by Physiologically Based Biopharmaceutics Modelling
by: Harri Dickinson, et al.
Published: (2025-05-01)

National Granted Programs and Public Funds for Biopharmaceutical Startups in Japan
by: Ryo Okuyama
Published: (2025-06-01)

Biopharmaceuticals. Official position of Russian Association of Endocrinologists
by: Editorial team Diabetes Mellitus
Published: (2013-09-01)

RETRACTED: The biopharmaceutical classiﬁcation of medicinal substances
by: G. V. Ramenskaya, et al.
Published: (2011-03-01)

Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation
by: Leonor S. Castro, et al.
Published: (2021-04-01)

Effects of Debt Financing Decisions on Profitability: A Comparison of USA and Europe Biopharmaceutical Industry
by: Emmanuel Nkansah
Published: (2025-07-01)

Yeasts as Biopharmaceutical Production Platforms
by: Natalja Kulagina, et al.
Published: (2021-09-01)

Research on incentive and technological innovation models of biopharmaceutical companies
by: Kexin Wang
Published: (2024-01-01)

A Model for Indigenous Development of Biopharmaceutical Industry: The Case of CinnaGen Company
by: Fatemeh Mojiri, et al.
Published: (2019-05-01)

Modification of biopharmaceutical parameters of flavonoids: a review
by: Amir Taldaev, et al.
Published: (2025-04-01)

Transcriptomics as a predictor of biopharmaceutically favourable glycan profiles
by: Ben West, et al.
Published: (2024-12-01)

Cyberbiosecurity for Biopharmaceutical Products
by: Jennifer L. Mantle, et al.
Published: (2019-05-01)

Potential and Constraints of Biopharmaceutical Plants in East Kalimantan Province
by: Junaidin Junaidin, et al.
Published: (2022-06-01)

Rowanberry—A Source of Bioactive Compounds and Their Biopharmaceutical Properties
by: Ofelia Marioara Arvinte, et al.
Published: (2023-09-01)

Research Progress of Marine-algae Biopharmaceutical Promoting the Construction of Maritime Power
by: Zian REN, et al.
Published: (2023-04-01)

Machine Learning Approaches for Enhancing Customer Retention and Sales Forecasting in the Biopharmaceutical Industry: A Case Study
by: Xiaowen Ma, et al.
Published: (2024-01-01)

Solubility evaluation of didanosine: a comparison between the equilibrium method and intrinsic dissolution for biopharmaceutics classification purposes
by: André Bersani Dezani, et al.
Published: (2017-08-01)

Important Factors in the Development of Biopharmaceutical Logistics Centers
by: Hyunjae Jung, et al.
Published: (2021-12-01)

Risk Factors of Supply Chain in Biopharmaceutical Companies in Iran
by: Hadi Abbasian, et al.
Published: (2021-09-01)

Biopharmaceuticals and Nutraceuticals Produced in Yeasts and the Clinical Management Related to COVID-19 Disease
by: Farzane Arianfar, et al.
Published: (2022-05-01)

Pharmacokinetics of Biopharmaceuticals: Their Critical Role in Molecular Design
by: Takuo Ogihara, et al.
Published: (2023-05-01)

DISINTEGRANTS AND THEIR INFLUENCE ON THE DISSOLUTION OF SUBSTANCES OF BIOPHARMACEUTICAL CLASSIFICATION SYSTEM CLASSES
by: I. E. Smekhova, et al.
Published: (2019-01-01)

Alternative buffer systems in biopharmaceutical formulations and their effect on protein stability
by: Lebar Blaž, et al.
Published: (2024-09-01)

Developments and opportunities in continuous biopharmaceutical manufacturing
by: Ohnmar Khanal, et al.
Published: (2021-01-01)

Biowaiver based on biopharmaceutics classification system: Considerations and requirements
by: Pratik R. Dhake, et al.
Published: (2024-12-01)